223 related articles for article (PubMed ID: 20153385)
21. A comparative study on the possible cytotoxic effects of different nanostructured lipid carrier (NLC) compositions in human dermal fibroblasts.
Brugè F; Damiani E; Marcheggiani F; Offerta A; Puglia C; Tiano L
Int J Pharm; 2015 Nov; 495(2):879-85. PubMed ID: 26392245
[TBL] [Abstract][Full Text] [Related]
22. Itraconazole-loaded nanostructured lipid carriers (NLC) for pulmonary treatment of aspergillosis in falcons.
Pardeike J; Weber S; Zarfl HP; Pagitz M; Zimmer A
Eur J Pharm Biopharm; 2016 Nov; 108():269-276. PubMed ID: 27449629
[TBL] [Abstract][Full Text] [Related]
23. Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats.
Zhang S; Wang J; Pan J
Drug Deliv; 2016 Nov; 23(9):3696-3703. PubMed ID: 27749105
[TBL] [Abstract][Full Text] [Related]
24. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies.
Vitorino C; Almeida A; Sousa J; Lamarche I; Gobin P; Marchand S; Couet W; Olivier JC; Pais A
Eur J Pharm Biopharm; 2014 Feb; 86(2):133-44. PubMed ID: 24333401
[TBL] [Abstract][Full Text] [Related]
25. Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats.
Nirbhavane P; Sharma G; Singh B; Khuller GK; Goni VG; Patil AB; Katare OP
AAPS PharmSciTech; 2018 Oct; 19(7):3187-3198. PubMed ID: 30143947
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of crystallization and growth of celecoxib nanoparticles formed from volatile microemulsions.
Margulis-Goshen K; Weitman M; Major DT; Magdassi S
J Pharm Sci; 2011 Oct; 100(10):4390-400. PubMed ID: 21630277
[TBL] [Abstract][Full Text] [Related]
27. Curcumin loaded nanostructured lipid carriers for enhanced skin retained topical delivery: optimization, scale-up, in-vitro characterization and assessment of ex-vivo skin deposition.
Rapalli VK; Kaul V; Waghule T; Gorantla S; Sharma S; Roy A; Dubey SK; Singhvi G
Eur J Pharm Sci; 2020 Sep; 152():105438. PubMed ID: 32598913
[TBL] [Abstract][Full Text] [Related]
28. Fabrication and evaluation of lipid nanoparticulates for ocular delivery of a COX-2 inhibitor.
Sharma AK; Sahoo PK; Majumdar DK; Sharma N; Sharma RK; Kumar A
Drug Deliv; 2016 Nov; 23(9):3364-3373. PubMed ID: 27128623
[TBL] [Abstract][Full Text] [Related]
29. Experimental study and mathematical modeling for encapsulation of fentanyl citrate drug in nanostructured lipid carrier.
Bahrami MA; Farhadian N
J Biomol Struct Dyn; 2020 Mar; 38(5):1263-1271. PubMed ID: 30990126
[TBL] [Abstract][Full Text] [Related]
30. Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer.
Lee R; Choi YJ; Jeong MS; Park YI; Motoyama K; Kim MW; Kwon SH; Choi JH
Bioconjug Chem; 2020 Mar; 31(3):923-932. PubMed ID: 32027493
[TBL] [Abstract][Full Text] [Related]
31. Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy.
Cirri M; Maestrini L; Maestrelli F; Mennini N; Mura P; Ghelardini C; Di Cesare Mannelli L
Drug Deliv; 2018 Nov; 25(1):1910-1921. PubMed ID: 30451015
[TBL] [Abstract][Full Text] [Related]
32. Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy.
Emami J; Pourmashhadi A; Sadeghi H; Varshosaz J; Hamishehkar H
Pharm Dev Technol; 2015 Nov; 20(7):791-800. PubMed ID: 24841045
[TBL] [Abstract][Full Text] [Related]
33. [Preparation of PEG-modified nanostructured lipid carriers loaded with hydroxycamptothecin and tissue distribution in mice].
Zhang XX; Gan Y; Yang XG; Zhu CL; Gan L; Nie SF; Pan WS
Yao Xue Xue Bao; 2008 Jan; 43(1):91-6. PubMed ID: 18357740
[TBL] [Abstract][Full Text] [Related]
34. Preparation and evaluation of PEGylated asiatic acid nanostructured lipid carriers on anti-fibrosis effects.
Chen X; Zhang Y; Zhao P; Chen Y; Zhou Y; Wang S; Yin L
Drug Dev Ind Pharm; 2020 Jan; 46(1):57-69. PubMed ID: 31813288
[TBL] [Abstract][Full Text] [Related]
35. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability.
Liu R; Liu Z; Zhang C; Zhang B
J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401
[TBL] [Abstract][Full Text] [Related]
36. Pulmonary Delivery of Docetaxel and Celecoxib by PLGA Porous Microparticles for Their Synergistic Effects Against Lung Cancer.
Ziaei E; Emami J; Rezazadeh M; Kazemi M
Anticancer Agents Med Chem; 2022; 22(5):951-967. PubMed ID: 34382530
[TBL] [Abstract][Full Text] [Related]
37. Effect of formulation variables on preparation of celecoxib loaded polylactide-co-glycolide nanoparticles.
Cooper DL; Harirforoosh S
PLoS One; 2014; 9(12):e113558. PubMed ID: 25502102
[TBL] [Abstract][Full Text] [Related]
38. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
39. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement.
Mandpe L; Pokharkar V
Pharm Dev Technol; 2015 May; 20(3):320-9. PubMed ID: 24328553
[TBL] [Abstract][Full Text] [Related]
40. Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery.
Shrivastava N; Khan S; Baboota S; Ali J
Curr Drug Deliv; 2018; 15(6):829-839. PubMed ID: 29189155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
